A detailed history of Deutsche Bank Ag\ transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 78,368 shares of VYGR stock, worth $452,967. This represents 0.0% of its overall portfolio holdings.

Number of Shares
78,368
Previous 70,648 10.93%
Holding current value
$452,967
Previous $558,000 17.92%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$5.77 - $9.27 $44,544 - $71,564
7,720 Added 10.93%
78,368 $458,000
Q2 2024

Aug 14, 2024

SELL
$7.42 - $10.54 $9,341 - $13,269
-1,259 Reduced 1.75%
70,648 $558,000
Q1 2024

May 15, 2024

BUY
$7.15 - $10.84 $43,765 - $66,351
6,121 Added 9.3%
71,907 $669,000
Q4 2023

Feb 14, 2024

BUY
$6.28 - $8.81 $5,991 - $8,404
954 Added 1.47%
65,786 $555,000
Q3 2023

Nov 09, 2023

SELL
$7.55 - $11.25 $23,737 - $35,370
-3,144 Reduced 4.63%
64,832 $502,000
Q2 2023

Aug 14, 2023

BUY
$6.94 - $13.99 $99,075 - $199,721
14,276 Added 26.58%
67,976 $778,000
Q1 2023

May 15, 2023

SELL
$6.0 - $10.78 $7,800 - $14,014
-1,300 Reduced 2.36%
53,700 $414,000
Q2 2022

Aug 11, 2022

BUY
$4.82 - $10.09 $265,100 - $554,950
55,000 New
55,000 $325,000
Q3 2021

Nov 04, 2021

SELL
$2.63 - $4.12 $1,659 - $2,599
-631 Closed
0 $0
Q2 2021

Aug 11, 2021

SELL
$3.94 - $5.44 $104,634 - $144,470
-26,557 Reduced 97.68%
631 $3,000
Q1 2021

May 13, 2021

SELL
$4.61 - $9.04 $112,613 - $220,829
-24,428 Reduced 47.33%
27,188 $128,000
Q4 2020

Feb 16, 2021

SELL
$7.15 - $12.28 $224,381 - $385,370
-31,382 Reduced 37.81%
51,616 $369,000
Q3 2020

Nov 12, 2020

BUY
$10.01 - $13.75 $311,871 - $428,395
31,156 Added 60.1%
82,998 $886,000
Q2 2020

Aug 13, 2020

BUY
$8.05 - $14.21 $341,432 - $602,702
42,414 Added 449.87%
51,842 $654,000
Q1 2020

May 14, 2020

SELL
$6.8 - $14.66 $222,026 - $478,663
-32,651 Reduced 77.59%
9,428 $86,000
Q4 2019

Feb 14, 2020

BUY
$12.82 - $16.85 $394,009 - $517,867
30,734 Added 270.9%
42,079 $586,000
Q3 2019

Nov 14, 2019

SELL
$16.31 - $28.29 $109,391 - $189,741
-6,707 Reduced 37.15%
11,345 $194,000
Q2 2019

Aug 14, 2019

SELL
$19.18 - $27.88 $130,750 - $190,057
-6,817 Reduced 27.41%
18,052 $490,000
Q1 2019

May 15, 2019

SELL
$8.0 - $19.66 $970,912 - $2.39 Million
-121,364 Reduced 82.99%
24,869 $474,000
Q4 2018

Feb 14, 2019

BUY
$8.59 - $18.05 $58,729 - $123,407
6,837 Added 4.9%
146,233 $1.37 Million
Q3 2018

Dec 21, 2021

BUY
$17.11 - $21.74 $1.11 Million - $1.41 Million
64,899 Added 87.12%
139,396 $2.64 Million
Q3 2018

Nov 14, 2018

BUY
$17.11 - $21.74 $396,096 - $503,280
23,150 Added 45.09%
74,497 $1.41 Million
Q2 2018

Apr 21, 2020

BUY
$16.76 - $23.92 $200,097 - $285,580
11,939 Added 30.3%
51,347 $1 Million
Q2 2018

Aug 14, 2018

SELL
$16.76 - $23.92 $2.53 Million - $3.61 Million
-150,732 Reduced 79.27%
39,408 $769,000
Q1 2018

Oct 18, 2019

BUY
$16.16 - $31.31 $649,809 - $1.26 Million
40,211 Added 26.82%
190,140 $3.57 Million
Q1 2018

May 15, 2018

BUY
$16.16 - $31.31 $1.78 Million - $3.45 Million
110,333 Added 278.65%
149,929 $2.82 Million
Q4 2017

Feb 14, 2018

BUY
$12.26 - $25.88 $319,495 - $674,432
26,060 Added 192.52%
39,596 $655,000
Q3 2017

Nov 14, 2017

BUY
$8.37 - $20.59 $113,296 - $278,706
13,536
13,536 $278,000

Others Institutions Holding VYGR

About Voyager Therapeutics, Inc.


  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $223M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.